All Studies Meta Analysis Recent:

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Keyaerts et al., Biochem. Biophys. Res. Comm., 323:1, 8 October 2004, doi:10.1016/j.bbrc.2004.08.085

Aug 2004

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

HCQ for COVID-19

1st treatment shown to reduce risk in March 2020

^*, now with p < 0.00000000001 from 418 studies, recognized in 46 countries.

Lower risk for mortality, hospitalization, progression, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments. ^* >10% efficacy, ≥3 studies.

5,000+ studies for 104 treatments. c19hcq.org

In Vitro study for SARS-CoV-1. IC₅₀ of CQ for antiviral activity (8.8) is significantly lower than cytostatic activity CC₅₀ (261.3), selectivity index of 30. IC₅₀ for inhibition of SARS-CoV in vitro approximates the plasma concentrations of CQ reached during treatment of acute malaria. CQ may be considered for immediate use in the prevention and treatment of SARS-CoV infections.

38 preclinical studies support the efficacy of HCQ for COVID-19:

11 In Silico studies1-11

24 In Vitro studies1,12-34

3 In Vivo animal studies16,26,35

Important missing comments or errors? Let us know.

1. González-Paz et al., Biophysical Analysis of Potential Inhibitors of SARS-CoV-2 Cell Recognition and Their Effect on Viral Dynamics in Different Cell Types: A Computational Prediction from In Vitro Experimental Data, ACS Omega, doi:10.1021/acsomega.3c06968.acs.org, doi.org.

2. Alkafaas et al., A study on the effect of natural products against the transmission of B.1.1.529 Omicron, Virology Journal, doi:10.1186/s12985-023-02160-6.biomedcentral.com, doi.org.

3. Guimarães Silva et al., Are Non-Structural Proteins From SARS-CoV-2 the Target of Hydroxychloroquine? An in Silico Study, ACTA MEDICA IRANICA, doi:10.18502/acta.v61i2.12533.kne-publishing.com, doi.org.

4. Nguyen et al., The Potential of Ameliorating COVID-19 and Sequelae From Andrographis paniculata via Bioinformatics, Bioinformatics and Biology Insights, doi:10.1177/11779322221149622.sagepub.com, doi.org.

5. Navya et al., A computational study on hydroxychloroquine binding to target proteins related to SARS-COV-2 infection, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2021.100714.sciencedirect.com, doi.org.

6. Yadav et al., Repurposing the Combination Drug of Favipiravir, Hydroxychloroquine and Oseltamivir as a Potential Inhibitor Against SARS-CoV-2: A Computational Study, Research Square, doi:10.21203/rs.3.rs-628277/v1.researchsquare.com, doi.org.

7. Hussein et al., Molecular Docking Identification for the efficacy of Some Zinc Complexes with Chloroquine and Hydroxychloroquine against Main Protease of COVID-19, Journal of Molecular Structure, doi:10.1016/j.molstruc.2021.129979.sciencedirect.com, doi.org.

8. Baildya et al., Inhibitory capacity of Chloroquine against SARS-COV-2 by effective binding with Angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies, Journal of Molecular Structure, doi:10.1016/j.molstruc.2021.129891.sciencedirect.com, doi.org.

9. Noureddine et al., Quantum chemical studies on molecular structure, AIM, ELF, RDG and antiviral activities of hybrid hydroxychloroquine in the treatment of COVID-19: molecular docking and DFT calculations, Journal of King Saud University - Science, doi:10.1016/j.jksus.2020.101334.sciencedirect.com, doi.org.

10. Tarek et al., Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention, European Journal of Drug Metabolism and Pharmacokinetics, doi:10.1007/s13318-020-00640-6.springer.com, doi.org.

11. Rowland Yeo et al., Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1955.wiley.com, doi.org.

12. Hitti et al., Hydroxychloroquine attenuates double-stranded RNA-stimulated hyper-phosphorylation of tristetraprolin/ZFP36 and AU-rich mRNA stabilization, Immunology, doi:10.1111/imm.13835.wiley.com, doi.org.

13. Yan et al., Super-resolution imaging reveals the mechanism of endosomal acidification inhibitors against SARS-CoV-2 infection, ChemBioChem, doi:10.1002/cbic.202400404.wiley.com, doi.org.

14. Mohd Abd Razak et al., In Vitro Anti-SARS-CoV-2 Activities of Curcumin and Selected Phenolic Compounds, Natural Product Communications, doi:10.1177/1934578X231188861.sagepub.com, doi.org.

15. Alsmadi et al., The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel, AAPS PharmSciTech, doi:10.1208/s12249-023-02627-3.springer.com, doi.org.

16. Wen et al., Cholinergic α7 nAChR signaling suppresses SARS-CoV-2 infection and inflammation in lung epithelial cells, Journal of Molecular Cell Biology, doi:10.1093/jmcb/mjad048.oup.com, doi.org.

17. Kamga Kapchoup et al., In vitro effect of hydroxychloroquine on pluripotent stem cells and their cardiomyocytes derivatives, Frontiers in Pharmacology, doi:10.3389/fphar.2023.1128382.frontiersin.org, doi.org.

18. Milan Bonotto et al., Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection, Antiviral Research, doi:10.1016/j.antiviral.2023.105655.sciencedirect.com, doi.org.

19. Miao et al., SIM imaging resolves endocytosis of SARS-CoV-2 spike RBD in living cells, Cell Chemical Biology, doi:10.1016/j.chembiol.2023.02.001.sciencedirect.com, doi.org.

20. Yuan et al., Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture, Communications Biology, doi:10.1038/s42003-022-03841-8.nature.com, doi.org.

21. Faísca et al., Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2, Pharmaceutics, doi:10.3390/pharmaceutics14040877.mdpi.com, doi.org.

22. Delandre et al., Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants, Pharmaceuticals, doi:10.3390/ph15040445.mdpi.com, doi.org.

23. Purwati et al., An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia, PLOS One, doi:10.1371/journal.pone.0252302.plos.org, doi.org.

24. Zhang et al., SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination, Cell Death & Differentiation, doi:10.1038/s41418-021-00782-3.nature.com, doi.org.

25. Dang et al., Structural basis of anti-SARS-CoV-2 activity of hydroxychloroquine: specific binding to NTD/CTD and disruption of LLPS of N protein, bioRxiv, doi:10.1101/2021.03.16.435741.biorxiv.org, doi.org.

26. Shang et al., Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice, Virology Journal, doi:10.1186/s12985-021-01515-1.biomedcentral.com, doi.org.

27. Wang et al., Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus, Phytomedicine, doi:10.1016/j.phymed.2020.153333.nih.gov, doi.org.

28. Sheaff, R., A New Model of SARS-CoV-2 Infection Based on (Hydroxy)Chloroquine Activity, bioRxiv, doi:10.1101/2020.08.02.232892.biorxiv.org, doi.org.

29. Ou et al., Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2, PLOS Pathogens, doi:10.1371/journal.ppat.1009212.plos.org, doi.org.

30. Andreani et al., In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, Microbial Pathogenesis, doi:10.1016/j.micpath.2020.104228.sciencedirect.com, doi.org.

31. Clementi et al., Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro, Front. Microbiol., 10 July 2020, doi:10.3389/fmicb.2020.01704.frontiersin.org, doi.org.

32. Liu et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discovery 6, 16 (2020), doi:10.1038/s41421-020-0156-0.nature.com, doi.org.

33. Yao et al., In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis., 2020 Mar 9, doi:10.1093/cid/ciaa237.oup.com, doi.org.

34. Wang (B) et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res. 30, 269–271, doi:10.1038/s41422-020-0282-0.nature.com, doi.org.

35. Shu-Han Lin et al., Inhalable Chitosan-Based Hydrogel as a Mucosal Adjuvant for Hydroxychloroquine in the Treatment for SARS-CoV-2 Infection in a Hamster Model, Journal of Microbiology, Immunology and Infection, doi:10.1016/j.jmii.2023.08.001.sciencedirect.com, doi.org.

Keyaerts et al., 28 Aug 2004, peer-reviewed, 5 authors.

In Vitro studies are an important part of preclinical research, however results may be very different in vivo.

This Paper HCQ All

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Els Keyaerts, Leen Vijgen, Piet Maes, Johan Neyts, Marc Van Ranst

Biochemical and Biophysical Research Communications, doi:10.1016/j.bbrc.2004.08.085

We report on chloroquine, a 4-amino-quinoline, as an effective inhibitor of the replication of the severe acute respiratory syndrome coronavirus (SARS-CoV) in vitro. Chloroquine is a clinically approved drug effective against malaria. We tested chloroquine phosphate for its antiviral potential against SARS-CoV-induced cytopathicity in Vero E6 cell culture. Results indicate that the IC 50 of chloroquine for antiviral activity (8.8 ± 1.2 lM) was significantly lower than its cytostatic activity; CC 50 (261.3 ± 14.5 lM), yielding a selectivity index of 30. The IC 50 of chloroquine for inhibition of SARS-CoV in vitro approximates the plasma concentrations of chloroquine reached during treatment of acute malaria. Addition of chloroquine to infected cultures could be delayed for up to 5 h postinfection, without an important drop in antiviral activity. Chloroquine, an old antimalarial drug, may be considered for immediate use in the prevention and treatment of SARS-CoV infections.

References

Blau, Holmes, Human Coronavirus HCoV-229E enters susceptible cells via the endocytic pathway

Chan, Lai, Chu, Tsui, Tam et al., Treatment of severe acute respiratory syndrome with lopinavir/ ritonavir: a multicentre retrospective matched cohort study, Hong Kong Med. J

Charmot, Coulaud, Treatment of Plasmodium falciparum malaria in Africa (except cerebral malaria), Med. Trop

Chu, Cheng, Hung, Wong, Chan et al., HKU/UCH SARS study group, Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax

Cinatl, Michaelis, Scholz, Doerr, Role of interferons in the treatment of severe acute respiratory syndrome, Expert, Opin. Biol. Ther

Cinatl, Morgenstern, Bauer, Chandra, Rabenau et al., Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus, Lancet

Drosten, Gunther, Preiser, Van Der Werf, Brodt et al., Identification of a novel coronavirus in patients with severe acute respiratory syndrome, N. Engl. J. Med

Fronhoffs, Totzke, Stier, Wernert, Rothe et al., A method for the rapid construction of cRNA standard curves in quantitative real-time reverse transcription polymerase chain reaction, Mol. Cell. Probes

Goodwin, Holt, Downes, Marshall, Microculture tetrazolium assays: a comparison between two new tetrazolium salts, XTT and MTS, J. Immunol. Methods

Keyaerts, Vijgen, Chen, Maes, Hedenstierna et al., Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound, Int. J. Infect. Dis

Kouroumalis, Koskinas, Treatment of chronic active hepatitis B (CAH B) with chloroquine: a preliminary report, Ann. Acad. Med. Singapore

Ksiazek, Erdman, Goldsmith, Zaki, Peret et al., SARS Working Group, A novel coronavirus associated with severe acute respiratory syndrome, N. Engl. J. Med

Kuiken, Fouchier, Schutten, Rimmelzwaan, Van Amerongen et al., Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome, Lancet

Marra, Jones, Astell, Holt, Brooks-Wilson et al., The genome sequence of the SARS-associated coronavirus, Science

Ng, Tan, See, Ooi, Ling, Proliferative growth of SARS coronavirus in Vero E6 cells, J. Gen. Virol

Pardridge, Yang, Diagne, Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes, Immunol. Lett

Pauwels, Balzarini, Baba, Snoeck, Schols et al., Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds, J. Virol. Methods

Peiris, Lai, Poon, Guan, Yam et al., Coronavirus as a possible cause of severe acute respiratory syndrome, Lancet

Rota, Oberste, Monroe, Nix, Campagnoli et al., Characterization of a novel coronavirus associated with severe acute respiratory syndrome, Science

Savarino, Boelaert, Cassone, Majori, Cauda, Effects of chloroquine on viral infections: an old drug against todayÕs diseases?, Lancet Infect. Dis

Savarino, Gennero, Sperber, Boelaert, The anti-HIV-1 activity of chloroquine, J. Clin. Virol

Singh, Sidhu, Friedman, Maheshwari, Mechanism of enhancement of the antiviral action of interferon against herpes simplex virus-1 by chloroquine, J. Interferon Cytokine Res

Tsai, Nara, Kung, Oroszlan, Inhibition of human immunodeficiency virus infectivity by chloroquine, AIDS Res. Hum. Retroviruses

Wollheim, Hanson, Laurell, Chloroquine treatment in rheumatoid arthritis. Correlation of clinical response to plasma protein changes and chloroquine levels, Scand. J. Rheumatol

Wu, Jan, Chen, Hsieh, Hwang et al., Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide, Antimicrob. Agents Chemother

Yamamoto, Yang, Yoshinaka, Amari, Nakano et al., HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus, Biochem. Biophys. Res. Commun

Zhaori, Antiviral treatment of SARS: can we draw any conclusions?, CMAJ

{ 'indexed': {'date-parts': [[2024, 5, 4]], 'date-time': '2024-05-04T00:08:54Z', 'timestamp': 1714781334272}, 'reference-count': 28, 'publisher': 'Elsevier BV', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2004, 10, 1]], 'date-time': '2004-10-01T00:00:00Z', 'timestamp': 1096588800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2004, 10]]}, 'DOI': '10.1016/j.bbrc.2004.08.085', 'type': 'journal-article', 'created': {'date-parts': [[2004, 9, 14]], 'date-time': '2004-09-14T13:15:35Z', 'timestamp': 1095167735000}, 'page': '264-268', 'source': 'Crossref', 'is-referenced-by-count': 477, 'title': 'In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine', 'prefix': '10.1016', 'volume': '323', 'author': [ {'given': 'Els', 'family': 'Keyaerts', 'sequence': 'first', 'affiliation': []}, {'given': 'Leen', 'family': 'Vijgen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Piet', 'family': 'Maes', 'sequence': 'additional', 'affiliation': []}, {'given': 'Johan', 'family': 'Neyts', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marc Van', 'family': 'Ranst', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.bbrc.2004.08.085_bib1', 'unstructured': 'World Health Organization, 2003. Communicable Disease Surveillance and ' 'Response. Summary of probable SARS cases with onset of illness from 1 ' 'November 2002 to 31 July 2003. Available from: ' '<http://www.who.int/csr/sars/country/table2003_09_23/en/>. (revised 26 ' 'September 2003)'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib2', 'doi-asserted-by': 'crossref', 'first-page': '1967', 'DOI': '10.1056/NEJMoa030747', 'article-title': 'Identification of a novel coronavirus in patients with severe acute ' 'respiratory syndrome', 'volume': '348', 'author': 'Drosten', 'year': '2003', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib3', 'doi-asserted-by': 'crossref', 'first-page': '1953', 'DOI': '10.1056/NEJMoa030781', 'article-title': 'A novel coronavirus associated with severe acute respiratory syndrome', 'volume': '348', 'author': 'Ksiazek', 'year': '2003', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib4', 'doi-asserted-by': 'crossref', 'first-page': '263', 'DOI': '10.1016/S0140-6736(03)13967-0', 'article-title': 'Newly discovered coronavirus as the primary cause of severe acute ' 'respiratory syndrome', 'volume': '362', 'author': 'Kuiken', 'year': '2003', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib5', 'doi-asserted-by': 'crossref', 'first-page': '1319', 'DOI': '10.1016/S0140-6736(03)13077-2', 'article-title': 'Coronavirus as a possible cause of severe acute respiratory syndrome', 'volume': '361', 'author': 'Peiris', 'year': '2003', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib6', 'doi-asserted-by': 'crossref', 'first-page': '1394', 'DOI': '10.1126/science.1085952', 'article-title': 'Characterization of a novel coronavirus associated with severe acute ' 'respiratory syndrome', 'volume': '300', 'author': 'Rota', 'year': '2003', 'journal-title': 'Science'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib7', 'doi-asserted-by': 'crossref', 'first-page': '1399', 'DOI': '10.1126/science.1085953', 'article-title': 'The genome sequence of the SARS-associated coronavirus', 'volume': '300', 'author': 'Marra', 'year': '2003', 'journal-title': 'Science'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib8', 'first-page': '399', 'article-title': 'Treatment of severe acute respiratory syndrome with ' 'lopinavir/ritonavir: a multicentre retrospective matched cohort study', 'volume': '9', 'author': 'Chan', 'year': '2003', 'journal-title': 'Hong Kong Med. J.'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib9', 'doi-asserted-by': 'crossref', 'first-page': '252', 'DOI': '10.1136/thorax.2003.012658', 'article-title': 'Role of lopinavir/ritonavir in the treatment of SARS: initial ' 'virological and clinical findings', 'volume': '59', 'author': 'Chu', 'year': '2004', 'journal-title': 'Thorax'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib10', 'doi-asserted-by': 'crossref', 'first-page': '827', 'DOI': '10.1517/14712598.4.6.827', 'article-title': 'Role of interferons in the treatment of severe acute respiratory ' 'syndrome', 'volume': '4', 'author': 'Cinatl', 'year': '2004', 'journal-title': 'Expert. Opin. Biol. Ther.'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib11', 'first-page': '1165', 'article-title': 'Antiviral treatment of SARS: can we draw any conclusions?', 'volume': '169', 'author': 'Zhaori', 'year': '2003', 'journal-title': 'CMAJ'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib12', 'doi-asserted-by': 'crossref', 'first-page': '2045', 'DOI': '10.1016/S0140-6736(03)13615-X', 'article-title': 'Glycyrrhizin, an active component of liquorice roots, and replication ' 'of SARS-associated coronavirus', 'volume': '361', 'author': 'Cinatl', 'year': '2003', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib13', 'doi-asserted-by': 'crossref', 'first-page': '2693', 'DOI': '10.1128/AAC.48.7.2693-2696.2004', 'article-title': 'Inhibition of severe acute respiratory syndrome coronavirus replication ' 'by niclosamide', 'volume': '48', 'author': 'Wu', 'year': '2004', 'journal-title': 'Antimicrob. Agents Chemother.'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib14', 'doi-asserted-by': 'crossref', 'first-page': '719', 'DOI': '10.1016/j.bbrc.2004.04.083', 'article-title': 'HIV protease inhibitor nelfinavir inhibits replication of ' 'SARS-associated coronavirus', 'volume': '318', 'author': 'Yamamoto', 'year': '2004', 'journal-title': 'Biochem. Biophys. Res. Commun.'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib15', 'doi-asserted-by': 'crossref', 'first-page': '223', 'DOI': '10.1016/j.ijid.2004.04.012', 'article-title': 'Inhibition of SARS-coronavirus infection in vitro by ' 'S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound', 'volume': '8', 'author': 'Keyaerts', 'year': '2004', 'journal-title': 'Int. J. Infect. Dis.'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib16', 'doi-asserted-by': 'crossref', 'first-page': '722', 'DOI': '10.1016/S1473-3099(03)00806-5', 'article-title': 'Effects of chloroquine on viral infections: an old drug against today’s ' 'diseases?', 'volume': '3', 'author': 'Savarino', 'year': '2003', 'journal-title': 'Lancet Infect. Dis.'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib17', 'doi-asserted-by': 'crossref', 'first-page': '481', 'DOI': '10.1089/aid.1990.6.481', 'article-title': 'Inhibition of human immunodeficiency virus infectivity by chloroquine', 'volume': '6', 'author': 'Tsai', 'year': '1990', 'journal-title': 'AIDS Res. Hum. Retroviruses'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib18', 'doi-asserted-by': 'crossref', 'first-page': '45', 'DOI': '10.1016/S0165-2478(98)00096-0', 'article-title': 'Chloroquine inhibits HIV-1 replication in human peripheral blood ' 'lymphocytes', 'volume': '64', 'author': 'Pardridge', 'year': '1998', 'journal-title': 'Immunol. Lett.'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib19', 'doi-asserted-by': 'crossref', 'first-page': '131', 'DOI': '10.1016/S1386-6532(00)00139-6', 'article-title': 'The anti-HIV-1 activity of chloroquine', 'volume': '20', 'author': 'Savarino', 'year': '2001', 'journal-title': 'J. Clin. Virol.'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib20', 'first-page': '149', 'article-title': 'Treatment of chronic active hepatitis B (CAH B) with chloroquine: a ' 'preliminary report', 'volume': '15', 'author': 'Kouroumalis', 'year': '1986', 'journal-title': 'Ann. Acad. Med. Singapore'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib21', 'doi-asserted-by': 'crossref', 'first-page': '725', 'DOI': '10.1089/jir.1996.16.725', 'article-title': 'Mechanism of enhancement of the antiviral action of interferon against ' 'herpes simplex virus-1 by chloroquine', 'volume': '16', 'author': 'Singh', 'year': '1996', 'journal-title': 'J. Interferon Cytokine Res.'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib22', 'series-title': 'The Nidoviruses, Coronaviruses and Arteriviruses', 'first-page': '193', 'article-title': 'Human Coronavirus HCoV-229E enters susceptible cells via the endocytic ' 'pathway', 'author': 'Blau', 'year': '2001'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib23', 'doi-asserted-by': 'crossref', 'first-page': '99', 'DOI': '10.1006/mcpr.2002.0405', 'article-title': 'A method for the rapid construction of cRNA standard curves in ' 'quantitative real-time reverse transcription polymerase chain reaction', 'volume': '16', 'author': 'Fronhoffs', 'year': '2002', 'journal-title': 'Mol. Cell. Probes'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib24', 'doi-asserted-by': 'crossref', 'first-page': '309', 'DOI': '10.1016/0166-0934(88)90134-6', 'article-title': 'Rapid and automated tetrazolium-based colorimetric assay for the ' 'detection of anti-HIV compounds', 'volume': '20', 'author': 'Pauwels', 'year': '1988', 'journal-title': 'J. Virol. Methods'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib25', 'doi-asserted-by': 'crossref', 'first-page': '95', 'DOI': '10.1016/0022-1759(94)00277-4', 'article-title': 'Microculture tetrazolium assays: a comparison between two new ' 'tetrazolium salts, XTT and MTS', 'volume': '179', 'author': 'Goodwin', 'year': '1995', 'journal-title': 'J. Immunol. Methods'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib26', 'doi-asserted-by': 'crossref', 'first-page': '3291', 'DOI': '10.1099/vir.0.19505-0', 'article-title': 'Proliferative growth of SARS coronavirus in Vero E6 cells', 'volume': '84', 'author': 'Ng', 'year': '2003', 'journal-title': 'J. Gen. Virol.'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib27', 'first-page': '103', 'article-title': 'Treatment of Plasmodium falciparum malaria in Africa (except cerebral ' 'malaria)', 'volume': '50', 'author': 'Charmot', 'year': '1990', 'journal-title': 'Med. Trop.'}, { 'key': '10.1016/j.bbrc.2004.08.085_bib28', 'doi-asserted-by': 'crossref', 'first-page': '171', 'DOI': '10.3109/03009747809095649', 'article-title': 'Chloroquine treatment in rheumatoid arthritis. Correlation of clinical ' 'response to plasma protein changes and chloroquine levels', 'volume': '7', 'author': 'Wollheim', 'year': '1978', 'journal-title': 'Scand. J. Rheumatol.'}], 'container-title': 'Biochemical and Biophysical Research Communications', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0006291X0401839X?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0006291X0401839X?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2019, 2, 3]], 'date-time': '2019-02-03T19:51:04Z', 'timestamp': 1549223464000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0006291X0401839X'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2004, 10]]}, 'references-count': 28, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2004, 10]]}}, 'alternative-id': ['S0006291X0401839X'], 'URL': 'http://dx.doi.org/10.1016/j.bbrc.2004.08.085', 'relation': {}, 'ISSN': ['0006-291X'], 'subject': [], 'container-title-short': 'Biochemical and Biophysical Research Communications', 'published': {'date-parts': [[2004, 10]]}}

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0